{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:15:04Z","timestamp":1788552904515,"version":"build-2803163510"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dolutegravir-based regimens are now standard of care for human immunodeficiency virus treatment for millions of people around sub-Saharan Africa. To ensure its continued efficacy, monitoring of emerging drug resistance that inform a treatment strategy among those failing is crucial. In this report, we outline the US President\u2019s Emergency Plan for AIDS Relief to leverage viral load infrastructure to implement effective drug resistance surveillance in the countries it supports.<\/jats:p>","DOI":"10.1093\/infdis\/jiab382","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T19:10:28Z","timestamp":1626721828000},"page":"364-366","source":"Crossref","is-referenced-by-count":19,"title":["Monitoring Emerging Human Immunodeficiency Virus Drug Resistance in Sub-Saharan Africa in the Era of Dolutegravir"],"prefix":"10.1093","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-941X","authenticated-orcid":false,"given":"Juliana","family":"da Silva","sequence":"first","affiliation":[{"name":"Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Pals","sequence":"additional","affiliation":[{"name":"Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hackett","sequence":"additional","affiliation":[{"name":"Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"},{"name":"US Department of State, Washington, Dsitrict of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-877X","authenticated-orcid":false,"given":"Elliot","family":"Raizes","sequence":"additional","affiliation":[{"name":"Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"2022020201044556900_CIT0001","author":"World Health Organization","year":"2019"},{"key":"2022020201044556900_CIT0002","article-title":"Nucleosides and","author":"Paton","year":"2021"},{"key":"2022020201044556900_CIT0003","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"2022020201044556900_CIT0004","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2022020201044556900_CIT0005"},{"key":"2022020201044556900_CIT0006"},{"key":"2022020201044556900_CIT0007","author":"Pierre"},{"key":"2022020201044556900_CIT0009","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/infdis\/jix404","article-title":"Expansion of viral load testing and the potential impact on human immunodeficiency virus drug resistance","volume":"216","author":"Chun","year":"2017","journal-title":"J Infect Dis"},{"key":"2022020201044556900_CIT0010","author":"UNAIDS"},{"key":"2022020201044556900_CIT0011","author":"Spotlight","year":"2020"},{"key":"2022020201044556900_CIT0012","author":"Gillian Hunt","year":"2019"},{"key":"2022020201044556900_CIT0013","author":"PEPFAR","year":"2021"},{"key":"2022020201044556900_CIT0014","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab382\/39810846\/jiab382.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/3\/364\/42361021\/jiab382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/3\/364\/42361021\/jiab382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T01:05:12Z","timestamp":1643763912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/3\/364\/6324299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,20]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab382","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,7,20]]}}}